gimatecan
gimatecan is a pharmaceutical drug with 9 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
0
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor
A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.
A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
A Study of Gimatecan (ST1481) in Small Cell Lung Cancer
Clinical Trials (9)
A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor
A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.
A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
A Study of Gimatecan (ST1481) in Small Cell Lung Cancer
Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors
A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9